View ValuationNovacyt 향후 성장Future 기준 점검 1/6Novacyt의 수익이 증가할 것으로 예상됨입니다.핵심 정보n/a이익 성장률n/aEPS 성장률Biotechs 이익 성장25.2%매출 성장률13.0%향후 자기자본이익률n/a애널리스트 커버리지Low마지막 업데이트10 Oct 2025최근 향후 성장 업데이트공시 • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.공시 • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.공시 • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).공시 • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).모든 업데이트 보기Recent updates공시 • 10hNovacyt S.A., Annual General Meeting, Jun 30, 2026Novacyt S.A., Annual General Meeting, Jun 30, 2026. Location: hotel hilton paris charles de gaulle aeroport, paris France공시 • May 21Novacyt S.A. Launches Yourgene Insight DPYD AssayNovacyt S.A. announced the launch of Yourgene Insight DPYD assay, an assay utilizing genetic Insights for safer chemotherapy treatments to align with updated testing guidelines. Yourgene Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients globally are treated with fluoropyrimidines (including 5-FU) each year; 10-20% of these patients suffer severe, and sometimes fatal side effects associated with DPD deficiency. Screening patients for DPYD variants allows treatments to be adjusted accordingly. Following updated guidelines from a joint consensus of organizations such as AMP (Association for Molecular Pathology) and ACMG (American College of Medical Genetics and Genomics), the 2019 original Yourgene DPYD test has been enhanced to enable the number of variants to be detected to increase from six to 19, including the 14 recommended by these updated guidelines. The product has been launched for Research Use Only (RUO) initially with In Vitro Diagnostic Regulation (IVDR) and other regulatory territory approvals to follow in due course. Many countries have already implemented DPYD genotyping ahead of prescribing chemotherapy treatment and there is a mixed model of private pay and reimbursement. The Yourgene Insight DPYD test has the same workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day, ensuring there is no delay in patients starting their chemotherapy treatment. The Company has continued to invest in research and development to expand its product portfolio, and it is encouraging to see this investment translating into commercially launched products and tangible pipeline progress.공시 • May 10Novacyt S.A. Announces Departure of Chief Scientific Officer and Board Member Dr Joanne Mason, Effective 7 May 2026Novacyt S.A. announces that Dr Joanne Mason is stepping down as Chief Scientific Officer and a member of the Board of Novacyt, with immediate effect, to enable her to pursue other business opportunities.공시 • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.공시 • Apr 08Novacyt S.A. to Report Fiscal Year 2025 Results on Apr 30, 2026Novacyt S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026공시 • Mar 03Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million.Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,961,840 Price\Range: €0.4 Transaction Features: Rights Offering공시 • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.공시 • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).공시 • Sep 18Novacyt S.A. to Report First Half, 2025 Results on Sep 30, 2025Novacyt S.A. announced that they will report first half, 2025 results on Sep 30, 2025공시 • Jul 16Novacyt S.A. Announces the Launch of LightBench® DiscoverNovacyt S.A. announced the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. The concept for the LightBench® Discover was developed following a close collaboration with PacBio®, where Yourgene Health became a PacBio® Compatible Partner for the original LightBench®? in November 2023. As part of product development for LightBench® Discover, Novacyt deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real world samples to assess the instruments' performance. LightBench® Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench®? Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench®) for large fragment analytics up to 150 kilobases, along with size selection and quantification functions, making it ideal for research applications utilising long read sequencing on the PacBio Revio®? or Vegatm systems. The Company has released the Technical Note showcasing data from its collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website <URL> and on the PacBio®? Compatible Partners webpage.공시 • May 15Novacyt S.A., Annual General Meeting, Jun 19, 2025Novacyt S.A., Annual General Meeting, Jun 19, 2025. Location: hotel hilton paris charles de gaulle aeroport, velizy villacoublay France공시 • Apr 22Novacyt S.A. to Report Fiscal Year 2024 Results on Apr 30, 2025Novacyt S.A. announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 30, 2025공시 • Feb 22Novacyt S.A. Announces IVDR Accreditation for Yourgene®? QST*R Base AssayNovacyt S.A. announced that it has receivedaccreditation under the new EU requirements of theIn VitroDiagnostic Regulation ("IVDR") for theYourgene® QSTRBaseassay.TheYourgene® QSTRBaseis a Class Cin vitromedical device under IVDR and is intended for use by healthcare professionals within a molecular laboratory environment. Yourgene® QSTR Base is a highly multiplexed, single tube assay containing 22 markers for rapid diagnosis of the common autosomal and sex chromosome aneuploidies during pregnancy. For those women identified as being at high risk of carrying a fetus with one of these conditions, chorionic villus sampling (10-12 weeks) or amniocentesis (14-18 weeks) is offered and QSTR Base would then be used by the laboratory. Autosomal markers are used to detect the three most common viable autosomal trisomies: trisomy 21 (Down's syndrome), trisomy 18 (Edwards' syndrome) and trisomy 13 (Patau's syndrome). The chosen markers are highly informative with results obtained in >99% of samples. IVDR ensures that the Yourgene® QSTR Base assay, which is manufactured for sale in the EU, is assessed against stringent quality, safety and performance requirements. Manufacturers must provide considerable evidence of scientific validity, as well as data demonstrating analytical and clinical performance of the tests. The Yourgene® QSTR Base assay was assessed by British Standards Institution (BSI), an independent conformity assessment body, and was shown to conform to the new regulations.공시 • Oct 08Novacyt S.A. Closure of IT-IS International LimitedNovacyt S.A. announced the closure of its IT-IS International Limited ("IT-IS") subsidiary, effective immediately. IT-IS, a Stokesley-based manufacturer of rapid-PCR instruments, was acquired by Novacyt in 2020 to support the Group's response to COVID-19, where it facilitated the full delivery of the Group's contracts during the period. The PCR instrumentation market has since become saturated, with IT-IS subsequently experiencing several consecutive loss-making years. IT-IS contributed £0.3m to the Group's total revenue in H1 2024 (H1 2023: £0.6million). The Intellectual Property ("IP") that exists within IT-IS will be retained to allow Novacyt to continue an ongoing IP infringement dispute with Roche Diagnostics GmbH. The dispute, instigated by IT-IS, dates back over five years and is currently progressing through the German courts. The Group will provide further updates on the dispute when appropriate.공시 • Sep 26Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024Novacyt S.A. announces the appointment of Dr. John Brown CBE as Chairman effective from 1 October 2024. Dr. Brown was appointed Non-executive Director of Novacyt in September 2023 following the acquisition of Yourgene Health and will succeedJames Wakefield, who is retiring from the Board having been Chairman since before the company joined AIM in 2017. Dr. Brown has over 38 years industry experience, which includes significant capital markets and board experience in the healthcare and life sciences sector. He is currently Chairman of Laverock Therapeutics Ltd. and Calcivis Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd. and CXR Biosciences Ltd. and Senior Non-Executive Director of Quantum Pharma plc. Dr. Brown was appointed to the Board of Yourgene Health in July 2019 as a Non-executive Director and became Chairman in April 2022.공시 • Sep 12Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024Novacyt S.A. announced that they will report first half, 2024 results on Sep 26, 2024공시 • May 22Novacyt S.A., Annual General Meeting, Jun 26, 2024Novacyt S.A., Annual General Meeting, Jun 26, 2024. Location: velizy villacoublay France공시 • May 21Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024Novacyt S.A. announced that they will report fiscal year 2023 results on May 30, 2024공시 • May 01Novacyt S.A. Notes DHSC Application for Summary Judgment DismissedNovacyt S.A. noted the judgment by Mrs. Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs. Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment. The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.공시 • Apr 12+ 1 more updateNovacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024Novacyt S.A. announced that James McCarthy will step down from the Board, effective from 1 May 2024. Dr. Andrew Health, Non-Executive Director will retire from the Board of Directors effective 1 May 2024.공시 • Sep 13Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023Novacyt S.A. announced that they will report Q2, 2023 results on Sep 28, 2023공시 • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).공시 • May 10Novacyt S.A., Annual General Meeting, Jun 15, 2023Novacyt S.A., Annual General Meeting, Jun 15, 2023, at 14:00 Central European Standard Time.이익 및 매출 성장 예측OTCPK:NVYT.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (GBP Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/202726N/A-5N/A112/31/202623N/A-7N/A112/31/202520N/A-12N/A16/30/202519-28-8-6N/A3/31/202520-34-10-8N/A12/31/202420-39-12-10N/A6/30/202417-33-30-29N/A3/31/202414-29-28-27N/A12/31/202311-24-26-25N/A9/30/20239-25-22-22N/A6/30/20238-25-18-18N/A3/31/202314-24-16-16N/A12/31/202221-22-14-14N/A9/30/202239-1156N/A6/30/20225712426N/A3/31/202275-21821N/A12/31/202193-61216N/A9/30/2021179403942N/A6/30/2021266856669N/A3/31/20212721098486N/A12/31/2020277132102103N/A9/30/2020173836162N/A6/30/202068332121N/A3/31/202040151010N/A12/31/201911-3-1-1N/A9/30/201912-3-10N/A6/30/201913-2-10N/A3/31/201912-2N/A-1N/A12/31/201812-2N/A-1N/A6/30/201811-3N/A-4N/A3/31/201811-3N/A-4N/A12/31/201711-3N/A-4N/A9/30/201712-4N/A-3N/A6/30/201712-3N/A-3N/A3/31/201710-4N/A-2N/A12/31/20169-5N/A-2N/A9/30/20169-9N/A-3N/A6/30/20168-13N/A-3N/A3/31/20167-12N/A-4N/A12/31/20157-10N/A-4N/A9/30/20156-7N/A-4N/A6/30/20156-4N/A-4N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: NVYT.F 의 예상 수익 증가율이 절약률(3.4%)보다 높은지 판단하기에는 데이터가 부족합니다.수익 vs 시장: NVYT.F 의 수익이 US 시장보다 빠르게 성장할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.고성장 수익: NVYT.F 의 수익이 향후 3년 동안 상당히 증가할 것으로 예상되는지 판단하기에는 데이터가 부족합니다.수익 대 시장: NVYT.F 의 수익(연간 13%)이 US 시장(연간 11.7%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: NVYT.F 의 수익(연간 13%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: NVYT.F의 자본 수익률이 3년 후 높을 것으로 예상되는지 판단하기에 데이터가 부족합니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/04/01 19:08종가2026/01/02 00:00수익2025/06/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Novacyt S.A.는 2명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Christophe-Raphael GanetODDO BHF Corporate & MarketsChristian GlennieStifel, Equities Research
공시 • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.
공시 • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.
공시 • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).
공시 • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).
공시 • 10hNovacyt S.A., Annual General Meeting, Jun 30, 2026Novacyt S.A., Annual General Meeting, Jun 30, 2026. Location: hotel hilton paris charles de gaulle aeroport, paris France
공시 • May 21Novacyt S.A. Launches Yourgene Insight DPYD AssayNovacyt S.A. announced the launch of Yourgene Insight DPYD assay, an assay utilizing genetic Insights for safer chemotherapy treatments to align with updated testing guidelines. Yourgene Insight DPYD is a simple-to-use genotyping test that can identify cancer patients with Dihydropyrimidine Dehydrogenase (DPD) deficiency, which can cause severe and sometimes lethal side effects in patients being treated with chemotherapeutic drug 5-Fluorouracil (5-FU), commonly used in the treatment of colorectal, head and neck, breast, pancreatic and stomach cancers. Over two million cancer patients globally are treated with fluoropyrimidines (including 5-FU) each year; 10-20% of these patients suffer severe, and sometimes fatal side effects associated with DPD deficiency. Screening patients for DPYD variants allows treatments to be adjusted accordingly. Following updated guidelines from a joint consensus of organizations such as AMP (Association for Molecular Pathology) and ACMG (American College of Medical Genetics and Genomics), the 2019 original Yourgene DPYD test has been enhanced to enable the number of variants to be detected to increase from six to 19, including the 14 recommended by these updated guidelines. The product has been launched for Research Use Only (RUO) initially with In Vitro Diagnostic Regulation (IVDR) and other regulatory territory approvals to follow in due course. Many countries have already implemented DPYD genotyping ahead of prescribing chemotherapy treatment and there is a mixed model of private pay and reimbursement. The Yourgene Insight DPYD test has the same workflow and format as the original DPYD kit, with ready-to-use reagents, simple data interpretation to identify the presence or absence of 19 variants and a fast turnaround time enabling results to be provided the same day, ensuring there is no delay in patients starting their chemotherapy treatment. The Company has continued to invest in research and development to expand its product portfolio, and it is encouraging to see this investment translating into commercially launched products and tangible pipeline progress.
공시 • May 10Novacyt S.A. Announces Departure of Chief Scientific Officer and Board Member Dr Joanne Mason, Effective 7 May 2026Novacyt S.A. announces that Dr Joanne Mason is stepping down as Chief Scientific Officer and a member of the Board of Novacyt, with immediate effect, to enable her to pursue other business opportunities.
공시 • May 02Novacyt S.A. Provides Earnings Guidance for Fiscal Year 2026Novacyt S.A. provided earnings guidance for Fiscal Year 2026. For the year, the company's outlook for FY26 looks strong, as company targets double digit revenue growth year-on-year.
공시 • Apr 08Novacyt S.A. to Report Fiscal Year 2025 Results on Apr 30, 2026Novacyt S.A. announced that they will report fiscal year 2025 results at 9:00 AM, Central European Standard Time on Apr 30, 2026
공시 • Mar 03Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million.Novacyt S.A. has filed a Follow-on Equity Offering in the amount of €0.784736 million. Security Name: Shares Security Type: Common Stock Securities Offered: 1,961,840 Price\Range: €0.4 Transaction Features: Rights Offering
공시 • Jan 21Novacyt S.A. Provides Earnings Guidance for the Second Half and Year Ended December 31, 2025Novacyt S.A. provided earnings guidance for the second half and year ended December 31, 2025. For the period, the company expects Group maintained sequential half-year growth over three consecutive periods, with revenue rising from £9.6 million in H2 2024 to £10.2 million in H2 2025 For the year, the company expects Group statutory revenue for Fiscal Year 2025 is expected to be c. £20.0 million (FY 2024: £19.6 million), in line with market expectations of £19.8 million.
공시 • Oct 22Novacyt S.A. Provides Earnings Guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026Novacyt S.A. provided earnings guidance for the Second Half of fiscal year 2025 and for the full fiscal year 2026. For the second half of fiscal year 2025, company expected to see a slight increase revenues vs first half of 2025, driven primarily by increased instrument sales, with new orders received from the recently launched LightBencx Discover instrument. For the fiscal year 2026, company expected to deliver double digit revenue growth year-on-year (from FY26).
공시 • Sep 18Novacyt S.A. to Report First Half, 2025 Results on Sep 30, 2025Novacyt S.A. announced that they will report first half, 2025 results on Sep 30, 2025
공시 • Jul 16Novacyt S.A. Announces the Launch of LightBench® DiscoverNovacyt S.A. announced the launch of LightBench® Discover, a high-precision 3-in-1 instrument for genomic research labs conducting long-read sequencing. The concept for the LightBench® Discover was developed following a close collaboration with PacBio®, where Yourgene Health became a PacBio® Compatible Partner for the original LightBench®? in November 2023. As part of product development for LightBench® Discover, Novacyt deployed prototype instruments into the field to gather customer feedback on user experience, develop protocols and run real world samples to assess the instruments' performance. LightBench® Discover is an integrated single benchtop solution that replaces the need for multiple instruments in labs conducting long-read HiFi sequencing, who need both large fragment analytics (larger than 20 kilobases) and DNA size selection. In addition, LightBench®? Discover also delivers fluorometric quantification. Researchers benefit from a cost-effective, high-performance system that enhances efficiency, whilst eliminating the need to invest in multiple instruments with separate service contracts and software platforms. The product has extended capabilities (compared to the original LightBench®) for large fragment analytics up to 150 kilobases, along with size selection and quantification functions, making it ideal for research applications utilising long read sequencing on the PacBio Revio®? or Vegatm systems. The Company has released the Technical Note showcasing data from its collaborator The CoLab at the HudsonAlpha Institute for Biotechnology in Alabama, US. The Technical Note will be hosted on the Company's website <URL> and on the PacBio®? Compatible Partners webpage.
공시 • May 15Novacyt S.A., Annual General Meeting, Jun 19, 2025Novacyt S.A., Annual General Meeting, Jun 19, 2025. Location: hotel hilton paris charles de gaulle aeroport, velizy villacoublay France
공시 • Apr 22Novacyt S.A. to Report Fiscal Year 2024 Results on Apr 30, 2025Novacyt S.A. announced that they will report fiscal year 2024 results at 9:00 AM, Central European Standard Time on Apr 30, 2025
공시 • Feb 22Novacyt S.A. Announces IVDR Accreditation for Yourgene®? QST*R Base AssayNovacyt S.A. announced that it has receivedaccreditation under the new EU requirements of theIn VitroDiagnostic Regulation ("IVDR") for theYourgene® QSTRBaseassay.TheYourgene® QSTRBaseis a Class Cin vitromedical device under IVDR and is intended for use by healthcare professionals within a molecular laboratory environment. Yourgene® QSTR Base is a highly multiplexed, single tube assay containing 22 markers for rapid diagnosis of the common autosomal and sex chromosome aneuploidies during pregnancy. For those women identified as being at high risk of carrying a fetus with one of these conditions, chorionic villus sampling (10-12 weeks) or amniocentesis (14-18 weeks) is offered and QSTR Base would then be used by the laboratory. Autosomal markers are used to detect the three most common viable autosomal trisomies: trisomy 21 (Down's syndrome), trisomy 18 (Edwards' syndrome) and trisomy 13 (Patau's syndrome). The chosen markers are highly informative with results obtained in >99% of samples. IVDR ensures that the Yourgene® QSTR Base assay, which is manufactured for sale in the EU, is assessed against stringent quality, safety and performance requirements. Manufacturers must provide considerable evidence of scientific validity, as well as data demonstrating analytical and clinical performance of the tests. The Yourgene® QSTR Base assay was assessed by British Standards Institution (BSI), an independent conformity assessment body, and was shown to conform to the new regulations.
공시 • Oct 08Novacyt S.A. Closure of IT-IS International LimitedNovacyt S.A. announced the closure of its IT-IS International Limited ("IT-IS") subsidiary, effective immediately. IT-IS, a Stokesley-based manufacturer of rapid-PCR instruments, was acquired by Novacyt in 2020 to support the Group's response to COVID-19, where it facilitated the full delivery of the Group's contracts during the period. The PCR instrumentation market has since become saturated, with IT-IS subsequently experiencing several consecutive loss-making years. IT-IS contributed £0.3m to the Group's total revenue in H1 2024 (H1 2023: £0.6million). The Intellectual Property ("IP") that exists within IT-IS will be retained to allow Novacyt to continue an ongoing IP infringement dispute with Roche Diagnostics GmbH. The dispute, instigated by IT-IS, dates back over five years and is currently progressing through the German courts. The Group will provide further updates on the dispute when appropriate.
공시 • Sep 26Novacyt S.A. Appoints John Brown Cbe as Chairman, Effective from 1 October 2024Novacyt S.A. announces the appointment of Dr. John Brown CBE as Chairman effective from 1 October 2024. Dr. Brown was appointed Non-executive Director of Novacyt in September 2023 following the acquisition of Yourgene Health and will succeedJames Wakefield, who is retiring from the Board having been Chairman since before the company joined AIM in 2017. Dr. Brown has over 38 years industry experience, which includes significant capital markets and board experience in the healthcare and life sciences sector. He is currently Chairman of Laverock Therapeutics Ltd. and Calcivis Ltd, and until recently was Chairman of Synpromics Ltd, BioCity Group and the Cell and Gene Therapy Catapult. Previously, he was Chairman of Kyowa Kirin International plc, BTG plc, Axis-Shield plc, Touch Bionics Ltd. and CXR Biosciences Ltd. and Senior Non-Executive Director of Quantum Pharma plc. Dr. Brown was appointed to the Board of Yourgene Health in July 2019 as a Non-executive Director and became Chairman in April 2022.
공시 • Sep 12Novacyt S.A. to Report First Half, 2024 Results on Sep 26, 2024Novacyt S.A. announced that they will report first half, 2024 results on Sep 26, 2024
공시 • May 22Novacyt S.A., Annual General Meeting, Jun 26, 2024Novacyt S.A., Annual General Meeting, Jun 26, 2024. Location: velizy villacoublay France
공시 • May 21Novacyt S.A. to Report Fiscal Year 2023 Results on May 30, 2024Novacyt S.A. announced that they will report fiscal year 2023 results on May 30, 2024
공시 • May 01Novacyt S.A. Notes DHSC Application for Summary Judgment DismissedNovacyt S.A. noted the judgment by Mrs. Justice Jefford following the Pre-Trial Review heard on 30 April 2024. Mrs. Justice Jefford has dismissed the application by the Department of Health and Social Care ("DHSC") for summary judgment. The Pre-Trial Review has now concluded, and the trial hearing has been listed to commence on 10 June 2024, and finish on 4 July 2024. The Company expects the court to reserve judgment, meaning that the outcome of the trial will not be known on 4 July 2024.
공시 • Apr 12+ 1 more updateNovacyt S.A. Announces Changes to Its Board, Effective on May 1, 2024Novacyt S.A. announced that James McCarthy will step down from the Board, effective from 1 May 2024. Dr. Andrew Health, Non-Executive Director will retire from the Board of Directors effective 1 May 2024.
공시 • Sep 13Novacyt S.A. to Report Q2, 2023 Results on Sep 28, 2023Novacyt S.A. announced that they will report Q2, 2023 results on Sep 28, 2023
공시 • Jul 28Novacyt S.A. Provides Group Revenue Guidance for the First Half Ended June 30, 2023Novacyt S.A. provided group revenue guidance for the first half ended June 30, 2023. Group revenue for first half 2023 expected to be £3.3 million of which £0.5 million relates to COVID-19 (first half 2022: £16.5 million of which £13.0 million relates to COVID-19).
공시 • May 10Novacyt S.A., Annual General Meeting, Jun 15, 2023Novacyt S.A., Annual General Meeting, Jun 15, 2023, at 14:00 Central European Standard Time.